AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMBBiotechnology
+$0.25 today
- Market cap
- $286.62M
- Beta
- 2.62
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$1.28
Volume 0.13M
Average 0.14M
AGMB Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
AgomAb Therapeutics N.V. American Depositary SharesNASDAQ: AGMB
Revenue · Q4 FY2024 · quarter ended Dec 2024
Revenue of €0 in Q4 FY2024
Q4 FY2024 revenue was €0.
Context
- Revenue increased in 0 of the last 2 fiscal years.
- FY2024 was the highest annual figure in the 3 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Revenue history
EUR · from the income statement
- Latest · FY2024
- 0 EUR
- Year-over-year change
- —
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Revenue vs competitors
How AGMB compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $232.39M USD | +107.7% | +183.6% | |
| LTM Mar 2026 | $8.37M USD | -52.9% | -35.9% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $7.4M USD | -63.1% | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | €0 EUR | — | — |
| LTM Mar 2026 | $0 USD | -100.0% | — | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — |
| Peer median (excluding AGMB) | — | -58.0% | +73.8% | |
Competitors are the stored peer set for AGMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin | — | — | — |
| Research & Development | 19.42M | 26.31M | 39.31M |
| Selling, General & Admin | 4.49M | 6M | 9.82M |
| Operating Expenses | 22.63M | 31.19M | 48.02M |
| Depreciation & Amortization | 23K | 99K | 311K |
| EBITDA | (10.74M) | (11.88M) | (45.89M) |
| EBITDA Margin | — | — | — |
| Operating Income | (22.63M) | (31.19M) | (48.02M) |
| Operating Margin | — | — | — |
| Interest Income | 71K | 245K | 1.22M |
| Interest Expense | 45K | 31K | 67K |
| Other Income / Expenses | 11.83M | 19.18M | 1.76M |
| Income Before Tax | (10.81M) | (12.01M) | (46.26M) |
| Pre-Tax Margin | — | — | — |
| Income Tax Expense | (2.66M) | (619K) | 4K |
| Net Income | (8.14M) | (11.39M) | (46.27M) |
| Net Margin | — | — | — |
| EPS (Basic) | (0.22) | (0.31) | (1.26) |
| EPS (Diluted) | (0.22) | (0.31) | (1.26) |
| Weighted Avg Shares | 36.24M | 36.24M | 36.24M |
| Weighted Avg Shares (Diluted) | 36.24M | 36.24M | 36.24M |
AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMB
Intrinsic Alpha fair value
Locked
Current Price
$5.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.